Log In
Print this Print this

biosimilar trastuzumab (ABP 980)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBiosimilar to trastuzumab
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation
PartnerAllergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today